1. Home
  2. SKYE vs WEYS Comparison

SKYE vs WEYS Comparison

Compare SKYE & WEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • WEYS
  • Stock Information
  • Founded
  • SKYE 2012
  • WEYS N/A
  • Country
  • SKYE United States
  • WEYS United States
  • Employees
  • SKYE N/A
  • WEYS N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • WEYS Apparel
  • Sector
  • SKYE Health Care
  • WEYS Consumer Staples
  • Exchange
  • SKYE Nasdaq
  • WEYS Nasdaq
  • Market Cap
  • SKYE 176.8M
  • WEYS 285.4M
  • IPO Year
  • SKYE N/A
  • WEYS N/A
  • Fundamental
  • Price
  • SKYE $5.89
  • WEYS $33.05
  • Analyst Decision
  • SKYE Strong Buy
  • WEYS
  • Analyst Count
  • SKYE 4
  • WEYS 0
  • Target Price
  • SKYE $19.25
  • WEYS N/A
  • AVG Volume (30 Days)
  • SKYE 384.5K
  • WEYS 15.3K
  • Earning Date
  • SKYE 01-01-0001
  • WEYS 08-06-2024
  • Dividend Yield
  • SKYE N/A
  • WEYS 3.17%
  • EPS Growth
  • SKYE N/A
  • WEYS N/A
  • EPS
  • SKYE N/A
  • WEYS 3.07
  • Revenue
  • SKYE N/A
  • WEYS $303,312,000.00
  • Revenue This Year
  • SKYE N/A
  • WEYS N/A
  • Revenue Next Year
  • SKYE N/A
  • WEYS N/A
  • P/E Ratio
  • SKYE N/A
  • WEYS $10.85
  • Revenue Growth
  • SKYE N/A
  • WEYS N/A
  • 52 Week Low
  • SKYE $1.44
  • WEYS $24.47
  • 52 Week High
  • SKYE $19.41
  • WEYS $33.70
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 34.36
  • WEYS 66.58
  • Support Level
  • SKYE $5.95
  • WEYS $28.13
  • Resistance Level
  • SKYE $6.83
  • WEYS $33.67
  • Average True Range (ATR)
  • SKYE 0.82
  • WEYS 0.92
  • MACD
  • SKYE 0.09
  • WEYS 0.43
  • Stochastic Oscillator
  • SKYE 21.26
  • WEYS 88.81

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale and the North American retail segment. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.

Share on Social Networks: